MRK 2Q19 results—Keytruda sales +63% YoY in constant currency. 2019 non-GAAP EPS guidance raised to $4.84-4.94 (from old range of $4.67-4.79). The midpoint of the new range represents 13% growth relative to 2018. PR: https://s21.q4cdn.com/488056881/files/doc_financials/2019/Q2/Merck-News-Release-07-30-19-Merck-Announces-Second-Quarter-2019-Financial-Results.pdf CC slides: https://s21.q4cdn.com/488056881/files/doc_financials/2019/Q2/Q219-Earnings-Deck_MRK.pdf